

QUARTERLY INVESTMENT REVIEW

International Developed Equity Allocation Fund

Performance returns (USD)

ANNUALIZED RETURNS (QUARTER-END)	Quarter-End	YTD	1-Year	3-Year	5-Year	10-Year	Since Inception
International Developed Equity Allocation Fund (net)	6.31	6.31	20.01	5.26	8.61	4.09	4.40
International Developed Equity Allocation Fund (gross)	6.47	6.47	20.76	5.91	9.28	4.74	5.04
MSCI EAFE	5.67	5.67	15.19	4.75	7.30	4.79	4.14
Value Add	+0.64	+0.64	+4.82	+0.52	+1.31	-0.69	+0.26

Major Performance Drivers

- Top-down asset allocation had a minor negative impact for the quarter, as the overweight position in emerging equities underperformed.
- Security selection was positive, driven by a good relative return in Developed Markets.

Emerging ex-China equities, with an emphasis on undervalued stocks within attractively valued countries/sectors, represented 8.0% of the total equity weight on average during the quarter. Our decision to hold a position in Emerging ex-China equities marginally detracted from relative performance as the MSCI Emerging ex-China Index returned 3.7% for the quarter, behind the MSCI EAFE index return of 5.7%. Security selection was also slightly negative, as the Emerging Market ex-China portfolio returned 2.3%. No Emerging Market securities featured in the top five biggest individual contributors or detractors at total portfolio level.

Developed ex-U.S. equities accounted for an average weight of 90.6% of the portfolio for the quarter, including the dedicated Japan Value position. This underweight position in Developed ex-U.S. had a small negative impact on relative performance as Developed Markets beat Emerging Markets. Security selection within Developed was solid for the quarter and the portfolio returned 6.8% in aggregate. An overweight position in Banco Bilbao (Spain Financials), Banco de Sabadell (Spain Financials), Stellantis (Italy Consumer Discretionary), and UniCredit (Italy Financials), along with an underweight position in Nestle (Switzerland Consumer Staples) featured in the top five biggest individual contributors. On the flipside, an underweight position in Novo Nordisk (Denmark Health Care), Toyota Motor (Japan Consumer Discretionary), and ASML (Netherlands Information Technology), along with an overweight position in STMicroelectronics (France Information Technology) and Equinor (Norway Energy) featured in the top five biggest detractors.

Portfolio weights, as a percent of equity, for the positions mentioned were: Banco Bilbao (2.5%), Banco de Sabadell (1.4%), Stellantis (2.1%), Nestle (0.0%), UniCredit (1.2%), Novo Nordisk (0.0%), Toyota Motor (0.0%), ASML (0.3%), STMicroelectronics (1.4%), Equinor (1.5%).

Inception Date: 5-Jun-06

Performance for the year of inception is less than a full calendar year. Returns shown for periods less than one year are not annualized.

Risks: Risks associated with investing in the Fund may include: (1) Market Risk - Equities: The market price of an equity may decline due to factors affecting the issuer or its industry or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. (3) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results. For a more complete discussion of these risks and others, please consult the Fund's prospectus. Annualized Returns may include the impact of purchase premiums and redemption fees. Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit www.gmo.com.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein. The local market in which the Fund is priced was closed for Good Friday on March 29, 2024. Therefore, the performance for the fund and corresponding benchmark will utilize March 28 for purposes of the ending valuation for the March return and the starting valuation for the April return. If certain expenses were not reimbursed, performance would be lower. Transaction costs, if any, are paid to the fund to offset the cost of portfolio transactions to invest or raise cash. **Net Expense Ratio: 0.62%; Gross Expense Ratio: 0.70%** Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2024. Elimination of this reimbursement will result in higher fees and lower performance. Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2023.

QUARTERLY INVESTMENT REVIEW

PRODUCT OVERVIEW

The Fund seeks to generate total return greater than that of the MSCI EAFE Index.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value, but mean reverts to appropriate valuation levels over the long term. Using GMO's 7-Year Asset Class Forecasts, the Fund seeks to allocate to areas of the global equity markets we believe are most attractively valued. Our approach combines the best of GMO's top-down Asset Allocation views and bottom-up equity research to identify mispricings at both the asset class and individual security levels. The Fund allocates to equity strategies that are actively managed by other GMO investment teams with expertise and experience in security selection within their respective markets. The Fund is allowed to invest up to 10% (at time of purchase) in emerging market equities.

IMPORTANT INFORMATION

Benchmark(s): The MSCI EAFE (Europe, Australasia, and Far East) Index (MSCI Standard Index Series, net of withholding tax) is an independently maintained and widely published index comprised of international large and mid capitalization stocks. MSCI data may not be reproduced or used for any other purpose. MSCI provides no warranties, has not prepared or approved this report, and has no liability hereunder.

An investor should consider the fund's investment objectives, risks, charges and expenses before investing. This and other important information can be found in the funds prospectus. To obtain a prospectus please visit www.gmo.com. Read the prospectus carefully before investing.

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.

ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO*

SINGAPORE

SYDNEY

TOKYO**

*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

**Representative Office